Stuttering priapism: Insights into pathogenesis and management

Current Urology Reports

Volumn 13, Issue 4, 2012, Pages 268-276

  Morrison, Belinda F ^a   Burnett, Arthur L ^b  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Androgen; Erectile dysfunction; Erection; Ischemicpriapism; Nitric oxide; Penis; Phosphodiesterase type 5; Priapism; Sicklecelldisease; Stuttering priapism

Indexed keywords

ADENOSINE; ANDROGEN; ANTIANDROGEN; CYCLIC GMP; DIETHYLSTILBESTROL; FINASTERIDE; GONADORELIN DERIVATIVE; HEME OXYGENASE; HYDROXYUREA; KETOCONAZOLE; NITRIC OXIDE; PREDNISONE; RHO KINASE;

ADRENERGIC SYSTEM; BLOOD VESSEL OCCLUSION; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVITY; ERYTHROCYTE TRANSFUSION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PENIS ERECTION; PRIAPISM; PROTEIN EXPRESSION; REVIEW; SEXUAL AROUSAL; SEXUAL FUNCTION; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANEMIA, SICKLE CELL; ERECTILE DYSFUNCTION; HUMANS; ISCHEMIA; MALE; PRIAPISM;

EID: 84864844050     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0258-9     Document Type: Review

References (63)

1. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Nehra A, Sharlip ID. American urological association guideline on the management of priapism. J Urol. 2003;170(4 Pt 1):1318-24.
2. Kulmala RV, Lehtonen TA, Tammela TL. Priapism, its incidence and seasonal distribution in Finland. Scand J Urol Nephrol. 1995;29(1):93-6.
3. Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. 2001;57(5):970-2.
4. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. 1980;140(11):1434-7.
5. Burnett AL, Bivalacqua TJ. Priapism: new concepts in medical and surgical management. Urol Clin North Am. 2011;38(2):185-94.
6. Hinman F. Priapism: report of cases and a clinical study of the literature with reference to its pathogenesis and surgical treatment. Ann Surg. 1914;60(6):689-716.
7. Burnett AL, Bivalacqua TJ. Glucose-6-phosphate dehydrogenase deficiency: an etiology for idiopathic priapism? J Sex Med. 2008;5 (1):237-40.
8. Prabhakaran K, Jacobs BL, Smaldone MC, Franks ME. Stuttering priapism associated with hereditary spherocytosis. Can J Urol. 2007;14(5):3702-4.
9. Dust N, Daboval T, Guerra L. Evaluation and management of priapism in a newborn: A case report and review of the literature. Paediatr Child Health. 2011;16(1):e6-8.
10. Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle-cell disease; incidence, risk factors and complications-an international multicentre study. BJU Int. 2002;90(9):898-902.
11. Giuliano F. Neurophysiology of erection and ejaculation. J Sex Med. 2011;8 Suppl 4:310-5.
12. Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res. 2004;16 Suppl 1:S15-9.
13. Trigo-Rocha F, Hsu GL, Donatucci CF, Lue TF. The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, en-dothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection. J Urol. 1993;149(4):872-7.
14. Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol. 2005;96(12B):29M-31M.
15. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83(4):1325-58.
16. Burnett AL, Musicki B. The nitric oxide signaling pathway in the penis. Curr Pharm Des. 2005;11(31):3987-94.
17. Srilatha B, Adaikan PG, Li L, Moore PK. Hydrogen sulphide: a novel endogenous gasotransmitter facilitates erectile function. J Sex Med. 2007;4(5):1304-11.
18. Liaw RL, Srilatha B, Adaikan PG. Effects of hydrogen sulfide on erectile function and its possible mechanism(s) of action. J Sex Med. 2011;8(7):1853-64.
19. Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol. 1986;135(1):142-7.
20. Burnett AL, Allen RP, Tempany CM, Dover GJ, Brendler CB. Evaluation of erectile function in men with sickle cell disease. Urology. 1995;45(4):657-63.
21. Datta NS. Megalophallus in sickle cell disease. J Urol. 1977;117 (5):672-3.
22. Elahi MM, Kong YX, Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev. 2009;2(5):259-69.
23. Kanika ND, Melman A, Davies KP. Experimental priapism is associated with increased oxidative stress and activation of protein degradation pathways in corporal tissue. Int J Impot Res. 2010;22 (6):363-73.
24. Ul-Hasan M, El-Sakka AI, Lee C, Yen TS, Dahiya R, Lue TF. Expression of TGF-beta-1 mRNA and ultrastructural alterations in pharmacologically induced prolonged penile erection in a canine model. J Urol. 1998;160(6 Pt 1):2263-6.
25. Muneer A, Cellek S, Dogan A, Kell PD, Ralph DJ, Minhas S. Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model. Int J Impot Res. 2005;17(1):10-8.
26. Filippi S, Marini M, Vannelli GB, Crescioli C, Granchi S, Vignozzi L, Luconi M, Ferruzzi P, Morelli A, Forti G, et al. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum. Mol Hum Reprod. 2003;9(12):765-74.
27. Broderick GA, Gordon D, Hypolite J, Levin RM. Anoxia and corporal smooth muscle dysfunction: a model for ischemic priap-ism. J Urol. 1994;151(1):259-62.
28. Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SE. Non-cholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl. 2002;23(1):92-7.
29. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A. 2005;102 (5):1661-6.
30. Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL, Champion HC. Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med. 2009;6(9):2494-504.
31. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL. Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol. 2007;51(6):1732-40.
32. Musicki B, Champion HC, Hsu LL, Bivalacqua TJ, Burnett AL. Post-translational inactivation of endothelial nitric oxide synthase in the transgenic sickle cell mouse penis. J Sex Med. 2011;8 (2):419-26.
33. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med. 2008;44 (8):1506-28.
34. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, Kadowitz PJ. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A. 2004;101(24):9121-6.
35. Bivalacqua TJ, Ross AE, Strong TD, Gebska MA, Musicki B, Champion HC, Burnett AL: Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell mice. Urology 2010, 76 (2):510 e517-512.
36. Phatarpekar PV, Wen J, Xia Y. Role of adenosine signaling in penile erection and erectile disorders. J Sex Med. 2010;7(11):3553-64.
37. Tostes RC, Giachini FR, Carneiro FS, Leite R, Inscho EW, Webb RC. Determination of adenosine effects and adenosine receptors in murine corpus cavernosum. J Pharmacol Exp Ther. 2007;322 (2):678-85.
38. Mi T, Abbasi S, Zhang H, Uray K, Chunn JL, Xia LW, Molina JG, Weisbrodt NW, Kellems RE, Blackburn MR, et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest. 2008;118 (4):1491-501.
39. Wen J, Jiang X, Dai Y, Zhang Y, Tang Y, Sun H, Mi T, Kellems RE, Blackburn MR, Xia Y. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med. 2010;7(9):3011-22.
40. Wen J, Jiang X, Dai Y, Zhang Y, Tang Y, Sun H, Mi T, Phatarpekar PV, Kellems RE, Blackburn MR, et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J. 2010;24(3):740-9.
41. Tong Y, Tar M, Monrose V, DiSanto M, Melman A, Davies KP. hSMR3A as a marker for patients with erectile dysfunction. J Urol. 2007;178(1):338-43.
42. Wisner A, Dufour E, Messaoudi M, Nejdi A, Marcel A, Ungeheuer MN, Rougeot C. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. Proc Natl Acad Sci U S A. 2006;103(47):17979-84.
43. Kanika ND, Tar M, Tong Y, Kuppam DS, Melman A, Davies KP. The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol. 2009;297(4):C916-27.
44. Shamloul R. The potential role of the heme oxygenase/carbon monoxide system in male sexual dysfunctions. J Sex Med. 2009;6(2):324-33.
45. Motterlini R, Hidalgo A, Sammut I, Shah KA, Mohammed S, Srai K, Green CJ. A precursor of the nitric oxide donor SIN-1 modulates the stress protein heme oxygenase-1 in rat liver. Biochem Biophys Res Commun. 1996;225(1):167-72.
46. Jin YC, Gam SC, Jung JH, Hyun JS, Chang KC. Expression and activity of heme oxygenase-1 in artificially induced low-flow priapism in rat penile tissues. J Sex Med. 2008;5(8):1876-82.
47. Traish AM, Guay AT. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006;3(3):382-404. discussion 404-387.
48. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med. 2005;2(6):759-70.
49. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145(5):2253-63.
50. Meusburger SM, Keast Jr. Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro. Neuroscience. 2001;108(2):331-40.
51. Serjeant GR, de Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet. 1985;2 (8467):1274-6.
52. Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology. 2002;59(1):138.
53. Steinberg J, Eyre RC. Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol. 1995;153(1):152-3.
54. Abern MR, Levine LA. Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol. 2009;182(4):1401-6.
55. Rachid-Filho D, Cavalcanti AG, Favorito LA, Costa WS, Sampaio FJ. Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach. Urology. 2009;74(5):1054-7.
56. Olujohungbe AB, Adeyoju A, Yardumian A, Akinyanju O, Morris J, Westerdale N, Akenova Y, Kehinde MO, Anie K, Howard J, et al. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial-the priapism in sickle cell study. J Androl. 2011;32(4):375-82.
57. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67(5):1043-8.
58. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sil-denafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol. 2005;68 (1):226-32.
59. Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med. 2002;113(3):252.
60. Tzortzis V, Mitrakas L, Gravas S, Mamoulakis C, Meissner A, Kyriakou D, Melekos MD. Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report. J Sex Med. 2009;6(7):2068-71.
61. Pierorazio PM, Bivalacqua TJ, Burnett AL. Daily phosphodies-terase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation. J Androl. 2011;32(4):371-4.
62. Saad ST, Lajolo C, Gilli S, Marques Junior JF, Lima CS, Costa FF, Arruda VR. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77(1):45-9.
63. Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol. 1993;150(5 Pt 1):1480-2.